Alterity Therapeutics (ASX:ATH) OCF Yield %: -14.54 (As of Jun. 27, 2026)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
34 GF Score
Price A$0.56
View Full Analysis

What is Alterity Therapeutics OCF Yield %?

Alterity Therapeutics ASX:ATH -1.75% 34 OCF Yield % is -14.54 as of Jun. 27, 2026. GuruFocus rates ASX:ATH with a GF Score™ of 34/100. Among 1,419 Biotechnology companies, Alterity Therapeutics ranks worse than 61.1% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Alterity Therapeutics's Trailing 12-Month Cash Flow from Operations is A$-17.71 Mil, and Market Cap is A$121.81 Mil. Therefore, Alterity Therapeutics's OCF Yield % for today is -14.54%.

The historical rank and industry rank for Alterity Therapeutics's OCF Yield % or its related term are showing as below:

ASX:ATH' s OCF Yield % Range Over the Past 10 Years
Min: -14.54   Med: 0   Max: -14.54
Current: -14.54


During the past 13 years, the highest OCF Yield % of Alterity Therapeutics was -14.54%. The lowest was -14.54%. And the median was %.

ASX:ATH's OCF Yield % is ranked worse than
61.1% of 1419 companies
in the Biotechnology industry
Industry Median: -8.48 vs ASX:ATH: -14.54

Alterity Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was %.


Alterity Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Alterity Therapeutics OCF Yield % Related Terms


Alterity Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics OCF Yield % Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.70 -39.43 -117.31 -60.08 -12.55

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.63 -10.32 -21.82 -24.28 0.00

ASX:ATH vs VRTX, REGN, ALNY: OCF Yield % Comparison

For the Biotechnology subindustry, Alterity Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's OCF Yield % falls into.


ASX:ATH
34GF Score
Alterity Therapeutics Ltd ASX:ATH
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Alterity Therapeutics's OCF Yield % for the fiscal year that ended in Jun. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-11.451 / 91.2735
=-12.55%

Alterity Therapeutics's annualized OCF Yield % for the quarter that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-5.281 * 4 / 87.0032
=-24.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -14.54 mean?
Alterity Therapeutics (ASX:ATH) has a OCF Yield % of -14.54 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Alterity Therapeutics and its competitors. According to the industry distribution chart, Alterity Therapeutics ranks #867 out of 1419 companies in the Biotechnology industry, placing it in the top 61.1%.
Is Alterity Therapeutics' OCF Yield % too high?
Alterity Therapeutics' current OCF Yield % is -14.54. Based on the distribution chart, Alterity Therapeutics ranks #867 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alterity Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #867 out of 1419 companies for OCF Yield %. This places Alterity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current OCF Yield % is -14.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current OCF Yield % of -14.54. The current OCF Yield % is -14.54. Alterity Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current OCF Yield % is -14.54 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for ASX:ATH

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price